CDT Equity Inc. (CDT) Form 8-K — Oct 27, 2026
$CDTForm 8-KItems 1.01, 3.02, 7.01, 9.01Filed Oct 27, 2026, 8:15 AM ET0001493152-26-048638Original filing
CDT Equity entered an Evaluation Agreement with Manoira Corporation on October 22, 2026, under which Manoira will assess CDT's clinical-stage compounds AZD1656 and AZD5904 in animal health applications alongside Manoira's planned cannabinoid-based products launching in Q1 2027. CDT pays Manoira a $195,000 fee entirely in stock: 1,347,616 shares at $0.1447. If the evaluation succeeds, the parties will negotiate a licensing and commercialization agreement over a 120-day window. Notably, Manoira's sole director is Dr.
Key figures
- Fee Usd
- 195000
- Issuance Price
- 0.1447
- Severance Value Usd
- 65000
- Shares Issued Manoira
- 1347616
- Shares Issued Sarborg
- 437779
- Shares Issued Severance
- 499616
- Shares Issued Service Provider
- 397374
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.